Trial Profile
Phase II Randomized Comparison Clinical Trial of Target Activated CIK for Advanced Lung Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti-CD3/MUC1-armed cytokine induced killer cells-Benhealth Biopharmaceutical (Primary)
- Indications Lung cancer
- Focus Therapeutic Use
- 13 Oct 2020 Planned End Date changed from 27 Mar 2021 to 27 Jul 2020.
- 13 Oct 2020 Status changed from recruiting to withdrawn prior to enrolment.
- 24 May 2020 Planned primary completion date changed from 27 Mar 2020 to 25 May 2020.